◀ Back to AKT3
AKT3 — PARP10
Text-mined interactions from Literome
Tapodi et al., J Biol Chem 2005
(Necrosis) :
These data together with the finding that
PARP inhibition in the absence of oxidative stress
induced the phosphorylation and activation of
Akt indicate that PARP inhibition induced Akt activation is dominantly responsible for the cytoprotection in oxidative stress
Szanto et al., Biochem Pharmacol 2009
:
To understand the
role of
Akt activation in the combined use of cytostatic agent and
PARP inhibition, we used taxol ( paclitaxel ) as an antineoplastic agent, which targets microtubules and up-regulates mitochondrial ROS production, together with ( i ) pharmacological inhibition ( PJ-34 ), ( ii ) siRNA knock-down and ( iii ) transdominant expression of the DNA binding domain of PARP-1
Gatson et al., Journal of neuroinflammation 2009
(Burns...) :
In addition, we determined that in the estrogen treated rats there was an increase in the levels of phospho-ERK ( p < 0.01 ) and
Akt ( p < 0.05 ) at the 24 hour time-point, and that 17 beta-estradiol
blocked the activation of caspase-3 ( p < 0.01 ) and subsequent cleavage of
PARP ( p < 0.05 )
Mallon et al., Mol Cancer Ther 2010
:
We are testing whether dual PI3K/mTOR inhibitors can durably suppress
p-Akt ,
induce cleaved
PARP , and cause tumor regression in a diverse set of human tumor xenograft models